All In Biotech

Drug Trial Radar · NCT00148733

CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia

Community- and Health Facility-based Intervention With Zinc as Adjuvant Therapy for Pneumonia to Enhance Child Health and Nutrition

Last checked: Nov 19, 2026Latest source record: Mar 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,628 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,628

Actual

Start

Jan 2004

Primary completion

Jan 2008

Study completion Jan 2008

Sponsor

Lead sponsor
Centre For International HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Tribhuvan University, Nepal; Statens Serum Institut; All India Institute of Medical Sciences; IRD, Epidemiologie et Prevention, Montpelier, France; Society for Applied Studies
First posted
Sep 8, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 2 months, up to 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study described is to measure the degree with which zinc given as adjunct therapy to standard antibiotic treatment during childhood pneumonia reduces the risk of treatment failure and the duration of the illness.

Conditions

  • Pneumonia

Interventions

  • ZincDrug

    Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Risk of Treatment Failure.Time frame: Within 2 weeks after enrollment
  2. Non-injury Clinic Visits and Hospital Admissions After Treatment Has Been InitiatedTime frame: Within 2 weeks after enrollment
  3. Active and Passive Morbidity Surveillance for Six Months After the 14-day Supplementation Period is CompletedTime frame: six months
  4. Difference in Growth and Thymic Size Between the Treatment Groups Measured at Three and Six Months After the Zinc SupplementationTime frame: six months
  5. Adverse EffectsTime frame: 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Siddhi Memorial Hospital (SMH),Bhelukhel, Bhimsensthan

    Bhaktapur, Nepal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.